Stargardt macular dystrophy

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Stargardt macular dystrophy (STGD1) is the leading inherited cause of macular degeneration.
• It results from ABCA4 gene variants, presenting genetic heterogeneity that complicates genotype-phenotype correlations.
• Pathophysiology involves visual cycle dysfunction, leading to lipofuscin accumulation and retinal cell damage.

Purpose of the Study:

• To summarize the current understanding of Stargardt macular dystrophy (STGD1).
• To highlight the genetic basis, clinical manifestations, and diagnostic approaches for STGD1.
• To review current management strategies and emerging therapeutic research for STGD1.

Main Methods:

• Review of existing literature on STGD1 genetics, pathophysiology, clinical features, diagnosis, and management.
• Analysis of genotype-phenotype correlations associated with different ABCA4 variants.
• Examination of current and emerging treatment modalities, including pharmacologic, gene, and stem cell therapies.

Main Results:

• STGD1 is caused by ABCA4 gene variants, with null variants linked to severe early-onset disease and missense/intronic variants to milder late-onset phenotypes.
• Clinical signs include central vision loss, macular atrophy, and retinal flecks due to lipofuscin accumulation.
• Diagnostic tools include OCT, fundus autofluorescence, ERG, and microperimetry.

Conclusions:

• STGD1 management focuses on supportive care and photoprotection, with no definitive treatments currently available.
• Ongoing research into pharmacologic, gene, and stem cell therapies offers future hope for vision preservation and restoration in STGD1 patients.
• Understanding genotype-phenotype correlations is crucial for predicting disease progression and tailoring management strategies.